On January 3, 2019 Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, reported that it will discuss its novel approach to antibody discovery and development and present data on its leading programs in a presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week (Press release, Compass Therapeutics, JAN 3, 2019, View Source [SID1234532418]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Thomas Schuetz, MD, PhD, co-founder and chief executive officer of Compass, will describe the company’s focus on drugging the broadest possible array of epitopes for each candidate target; its StitchMabs technology that identifies novel combination biology and enables the discovery of next-generation bispecific antibody drug candidates; and the company’s unbiased approach to drug discovery which empowers the identification of the most promising therapeutic for each tumor type and application.
CTX-471, a fully human monoclonal antibody which targets a unique epitope on the costimulatory receptor CD137, is Compass’ lead candidate, and it has the potential to become a best-in-class CD137 agonist. It is expected to enter the clinic in the first quarter of 2019 where it will be tested in patients with various solid tumors. In preclinical models, CTX-471 induces remodeling of the tumor microenvironment and can completely eradicate extremely large tumors in animals. In IND-enabling monkey toxicology studies, CTX-471 has an excellent safety profile.
The proprietary StitchMabs platform was used to discover Compass’ second clinical candidate which is a first-in-class bispecific NK cell engager that lowers the activation threshold of NK cells and directs NK cells to kill selected cells, including tumor cells with low target antigen expression.
The presentation details are:
Date: Tuesday, January 8
Time: 3 PM Pacific Time
Location: Westin St. Francis Hotel, San Francisco, Elizabethan C Room